Vigeo Therapeutics Advances VT1021 Into Phase 2-3 Registrational Study for Glioblastoma
/PRNewswire/ -- Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced its lead candidate VT1021 will...
Stay updated with breaking news from Adaptive Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced its lead candidate VT1021 will...
This randomized clinical trial evaluates the benefits and risks of the addition of a P2Y12 inhibitor to anticoagulant therapy compared with anticoagulant therap
The Luxembourg National Research Fund and Cancer Foundation Luxembourg will fund researchers using tumor models and transcriptomics to elucidate VAL-083's mechanism in GBM.
/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...
/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...